The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis

Abstract

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis

“…We compared our review with another published systematic review addressing corticosteroid therapy in COVID-19. 85 Apart from COVID-19, SARS and MERS, our review included 3 additional populations: ARDS, CAP and influenza. We updated our search until Apr.…”

Olfactory Dysfunction in the COVID-19 Outbreak

“…Yang et al, conducted a systematic review and meta-analysis concluding that CS use is associated with increased lung injury or shock and mortality in patients with CoV-pneumonia [72]. Although intranasal CSs are not recommended for sudden and severe smell loss in COVID-19 patients, when they are receiving them for the treatment of sinonasal diseases, such as rhinitis or chronic rhinosinusitis, drug discontinuation is not recommended [73].…”

Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS CoV-2: A Systematic Literature Review

“…The study found no statistically signi cant association between treatment with corticosteroids and virus clearance time (Hazards ratio (HR), 1.26; 95% CI, 0.58 to 2.74), hospital length of stay (HR, 0.77; 95% CI, 0.33 to 1.78), or duration of symptoms (HR, 0.86; 95% CI, 0.40 to 1.83) [34]. A recent meta-analysis also suggested a higher relative risk for mortality and longer length of stay in patients with SARS-CoV and MERS-CoV treated with corticosteroids [35].…”

“…The study concluded the superior effect of arbidol over lopinavir/ritonavir in the treatment of cases with mild to moderate SARS-CoV infection [44]. In another RCT, 86 patients with mild to moderate SARS-CoV-2 infection were randomly assigned to the lopinavir/ritonavir group (34) or the arbidol group (35) or the no antiviral drug group (17). The primary end point was virological cure.…”